David Baltimore - Amgen Independent Director
| AMGN Stock | USD 274.73 1.19 0.44% |
Director
Dr. David Baltimore, Ph.D., is an Independent Director of Amgen Inc. David Baltimore is President Emeritus and Robert Andrews Millikan Professor of Biology at the California Institute of Technology, or Caltech. He received the Nobel Prize in Medicine as a corecipient in 1975. Dr. Baltimore was a director of Regulus Therapeutics Inc., a biopharmaceutical company, since 2007, serving on its Compensation Committee and chairing its Nominating and Governance Committee, and is a member of its scientific advisory board since 1999.
| Age | 78 |
| Tenure | 25 years |
| Professional Marks | Ph.D |
| Address | One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 |
| Phone | 805 447 1000 |
| Web | https://www.amgen.com |
Amgen Management Efficiency
The company has return on total asset (ROA) of 0.0629 % which means that it generated a profit of $0.0629 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 1.3579 %, meaning that it created $1.3579 on every $100 dollars invested by stockholders. Amgen's management efficiency ratios could be used to measure how well Amgen manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Amgen's Return On Assets are very stable compared to the past year. As of the 24th of April 2024, Return On Equity is likely to grow to 1.13, while Return On Tangible Assets are likely to drop 0.12. At this time, Amgen's Return On Assets are very stable compared to the past year. As of the 24th of April 2024, Asset Turnover is likely to grow to 0.51, while Other Current Assets are likely to drop about 266.9 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Laurie Glimcher | Bristol Myers Squibb | 64 | |
| Wendell Weeks | Merck Company | 59 | |
| Robert Bertolini | Bristol Myers Squibb | 58 | |
| Dinesh Paliwal | Bristol Myers Squibb | 63 | |
| William Harrison | Merck Company | 70 | |
| Patricia Russo | Merck Company | 68 | |
| Pamela Craig | Merck Company | 64 | |
| Inge Thulin | Merck Company | 67 | |
| Vicki Sato | Bristol Myers Squibb | 71 | |
| Julia Haller | Bristol Myers Squibb | 66 | |
| Gerald Storch | Bristol Myers Squibb | 64 | |
| Peter Wendell | Merck Company | 70 | |
| Togo West | Bristol Myers Squibb | 72 | |
| Thomas Cech | Merck Company | 72 | |
| Karen Vousden | Bristol Myers Squibb | 63 | |
| Christine Seidman | Merck Company | 68 | |
| Craig Thompson | Merck Company | 64 | |
| John Noseworthy | Merck Company | 66 | |
| Jose Baselga | Bristol Myers Squibb | 57 | |
| Kathy Warden | Merck Company | 49 | |
| Thomas Glocer | Merck Company | 61 | |
Management Performance
| Return On Equity | 1.36 | ||||
| Return On Asset | 0.0629 |
Amgen Inc Leadership Team
Elected by the shareholders, the Amgen's board of directors comprises two types of representatives: Amgen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amgen. The board's role is to monitor Amgen's management team and ensure that shareholders' interests are well served. Amgen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amgen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Linda Louie, VP Officer | ||
| James MD, Executive Officer | ||
| Frank Herringer, Independent Director | ||
| Nancy Grygiel, Senior Officer | ||
| Francois Carbonnel, Independent Director | ||
| Rebecca Henderson, Independent Director | ||
| Annette Such, Chief Accounting Officer | ||
| Sanders Williams, Independent Director | ||
| Vance Coffman, Lead Independent Director | ||
| David Reese, Executive Vice President - Research and Development | ||
| Tyler Jacks, Independent Director | ||
| Brian McNamee, Executive Vice President - Full Potential Initiatives | ||
| Gregory Garland, Independent Director | ||
| Charles Holley, Director | ||
| Esteban Santos, Executive Vice President Operations | ||
| Jonathan Graham, Senior Vice President General Counsel, Secretary | ||
| Sean Harper, Executive Vice President - Research and Development | ||
| Mike Zahigian, Senior Officer | ||
| Ellen Kullman, Director | ||
| Frank Biondi, Independent Director | ||
| Arvind Sood, IR Contact Officer | ||
| David Meline, CFO and Executive VP | ||
| Ronald Sugar, Independent Director | ||
| Stuart Tross, Senior Vice President - Human Resources | ||
| Robert Bradway, Chairman, CEO and President Chairman of Executive Committee and Member of Equity Award Committee | ||
| Murdo Gordon, Executive Vice President of Global Commercial Operations | ||
| Peter Griffith, Executive CFO | ||
| Wanda Austin, Independent Director | ||
| Robert Eckert, Independent Director | ||
| Madhavan Balachandran, Executive VP of Operations | ||
| Lori Johnston, Senior Vice President - Human Resources | ||
| Brian Druker, Independent Director | ||
| Cynthia Patton, Senior Vice President Chief Compliance Officer | ||
| Greg Garland, Independent Director | ||
| Robert Williams, Independent Director | ||
| Justin Claeys, Vice Relations | ||
| Matthew Busch, Chief Finance | ||
| Judith Pelham, Independent Director | ||
| David Baltimore, Independent Director | ||
| Fred Hassan, Director | ||
| David Piacquad, Senior Vice President - Business Development | ||
| Anthony Hooper, Executive VP of Global Commercial Operations | ||
| Alan Russell, Vice Biologics | ||
| David MD, Executive Officer |
Amgen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amgen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 1.36 | ||||
| Return On Asset | 0.0629 | ||||
| Profit Margin | 0.24 % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 201.07 B | ||||
| Shares Outstanding | 536.38 M | ||||
| Shares Owned By Insiders | 0.25 % | ||||
| Shares Owned By Institutions | 80.00 % | ||||
| Number Of Shares Shorted | 10.47 M | ||||
| Price To Earning | 22.74 X |
Amgen Investors Sentiment
The influence of Amgen's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Amgen. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Amgen's public news can be used to forecast risks associated with an investment in Amgen. The trend in average sentiment can be used to explain how an investor holding Amgen can time the market purely based on public headlines and social activities around Amgen Inc. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Amgen's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Amgen's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Amgen's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Amgen.
Amgen Implied Volatility | 32.64 |
Amgen's implied volatility exposes the market's sentiment of Amgen Inc stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Amgen's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Amgen stock will not fluctuate a lot when Amgen's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Amgen in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Amgen's short interest history, or implied volatility extrapolated from Amgen options trading.
Pair Trading with Amgen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amgen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amgen will appreciate offsetting losses from the drop in the long position's value.Moving against Amgen Stock
| 0.79 | VKTX | Viking Therapeutics Earnings Call Today | PairCorr |
| 0.79 | LLY | Eli Lilly Earnings Call This Week | PairCorr |
| 0.73 | ELEV | Elevation Oncology Financial Report 20th of May 2024 | PairCorr |
| 0.67 | NRSNW | NeuroSense Therapeutics | PairCorr |
| 0.59 | XFOR | X4 Pharmaceuticals Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to Amgen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amgen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amgen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amgen Inc to buy it.
The correlation of Amgen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amgen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amgen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Amgen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Amgen Inc information on this page should be used as a complementary analysis to other Amgen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Complementary Tools for Amgen Stock analysis
When running Amgen's price analysis, check to measure Amgen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amgen is operating at the current time. Most of Amgen's value examination focuses on studying past and present price action to predict the probability of Amgen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amgen's price. Additionally, you may evaluate how the addition of Amgen to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |
Is Amgen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amgen. If investors know Amgen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amgen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.52) | Dividend Share 8.52 | Earnings Share 12.5 | Revenue Per Share 52.692 | Quarterly Revenue Growth 0.198 |
The market value of Amgen Inc is measured differently than its book value, which is the value of Amgen that is recorded on the company's balance sheet. Investors also form their own opinion of Amgen's value that differs from its market value or its book value, called intrinsic value, which is Amgen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amgen's market value can be influenced by many factors that don't directly affect Amgen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amgen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Amgen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amgen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.